A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer-Reference-Cited by-同舟云学术

A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer

Published:2020-01-02 Issue:5 Volume:38 Page:1533-1539
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Goyal Lipika,Chaudhary Surendra Pal^ORCID,Kwak Eunice L.,Abrams Thomas A.,Carpenter Amanda N.,Wolpin Brian M.,Wadlow Raymond C.,Allen Jill N.,Heist Rebecca,McCleary Nadine Jackson,Chan Jennifer A.,Goessling Wolfram,Schrag Deborah,Ng Kimmie,Enzinger Peter C.,Ryan David P.,Clark Jeffrey W.

Funder

National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-019-00889-y.pdf

Reference24 articles.

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492

2. Sohda M, Kuwano H (2017) Current status and future prospects for Esophageal Cancer treatment. Annals of Thoracic and Cardiovascular Surgery : Official Journal of the Association of Thoracic and Cardiovascular Surgeons of Asia 23(1):1–11. https://doi.org/10.5761/atcs.ra.16-00162

3. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet (London, England) 376(9742):687–697. https://doi.org/10.1016/s0140-6736(10)61121-x